Abstract 34P
Background
Resilience to stress is a central phenotype underlying cancer cell biology. Cancer resilience empowers cell growth and survival in the face of harsh microenvironments, cytotoxic therapies, and loss of normal cellular regulatory processes. By understanding the mechanisms underlying cancer cell resilience, we may develop therapies which constrain tumors generally or synergize with existing drugs. Here, we sought to identify yet-unknown mechanisms by which cancer cells orchestrate resilience.
Methods
Using genome-scale CRISPR-Cas9 screening data from over 700 unique cancer cell lines (DepMap project), we developed a guilt-by-association “coessentiality” approach to identify genes involved cellular stress response signaling. We then used a combination of molecular biology, evolutionary biology, and computational biology approaches to validate predictions.
Results
Using an unbiased functional genomic approach and subsequent molecular validation, we identified HAPSTR1 (formerly: C16orf72) as a gene which becomes particularly important to cancer cells under stress conditions (e.g., DNA damage, protein aggregation, nutrient starvation). HAPSTR1, despite conservation through worms, yeast, and plants, had no known function. We found that HAPSTR1 encodes a dimeric protein which enables nuclear localization of HUWE1, an otherwise cytoplasmic ubiquitin ligase. Additionally, we show that mammals have a second HAPSTR gene, HAPSTR2 (formerly: RP11-364B14.3), which formed via an atypical evolutionary mechanism and functions to buffer the HAPSTR-HUWE1 pathway in specific cancer subsets.
Conclusions
Altogether, we present a new gene family and biochemical pathway leveraged by cancer cells to empower resilience. Disruption of this pathway broadly impairs stress response regulation and may thus be relevant to understanding and targeting resilience in human tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Institutes of Health (NIH-USA).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - Multivariate analysis of functional organoid assays predicts patient responses in the clinic for colorectal and pancreatic cancer
Presenter: Anna-Rose Gryspeert
Session: Poster session 07
11P - Therapeutic effects of MRTX1133 in KRAS G12D mutant appendiceal cancer: Insights from organoid and in vivo studies
Presenter: John Paul Shen
Session: Poster session 07
12P - STING-activable pyroptotic nanoparticles deliver GSDMDNT mRNA for in situ pancreatic cancer vaccination and immunotherapy
Presenter: Shiyi Shao
Session: Poster session 07
Resources:
Abstract
14P - EED inhibition renders vulnerability to immunotherapy by rewiring ceramide metabolism in pancreatic cancer
Presenter: Fan Chen
Session: Poster session 07
15P - TIGIT+ CD8+ T cells limit the efficacy of PD-L1 blockade plus chemoradiotherapy in MSS locally advanced rectal cancer via NECTIN2-TIGIT interplay
Presenter: Zhehui Zhu
Session: Poster session 07
16P - PTEN deficiency leads to colorectal cancer immune evasion via atypical Keap1/Nrf2 pathway
Presenter: RunKai Cai
Session: Poster session 07
17P - Breaking chemotherapy resistance in gastric adenocarcinoma: Immunogenic cell death induction by carbonic anhydrase IX targeting
Presenter: Elena Andreucci
Session: Poster session 07
18P - The role of CTNNA1 truncating variants in hereditary diffuse gastric cancer (HDGC)
Presenter: Silvana Lobo
Session: Poster session 07
19P - KSR1 as a therapeutic target for hepatocellular carcinoma with activated RAS-RAF-MEK-ERK signaling pathway
Presenter: HYUK MOON
Session: Poster session 07
20P - Preclinical characterization of FGFR1-4 variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 07